Taken together these results support a hypothesis where downregulation of MGMT and accumulation of DNA damage in S-phase of combination treated TMZ-resistant glioblastoma cells serve to activate homologous recombination pathway (Ganesa et al., 2022). The gene discussed is MGMT; the disease is glioblastoma.